BrightGene Bio-Medical Technology Co Ltd
SSE:688166

Watchlist Manager
BrightGene Bio-Medical Technology Co Ltd Logo
BrightGene Bio-Medical Technology Co Ltd
SSE:688166
Watchlist
Price: 31.54 CNY 2.1% Market Closed
Market Cap: 13.3B CNY
Have any thoughts about
BrightGene Bio-Medical Technology Co Ltd?
Write Note

Gross Margin
BrightGene Bio-Medical Technology Co Ltd

55%
Current
57%
Average
48.3%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
55%
=
Gross Profit
682.4m
/
Revenue
1.2B

Gross Margin Across Competitors

Country CN
Market Cap 13.3B CNY
Gross Margin
55%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 749.7B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 3.3T DKK
Gross Margin
85%
Country US
Market Cap 372B USD
Gross Margin
69%
Country US
Market Cap 257.3B USD
Gross Margin
77%
Country CH
Market Cap 201.7B CHF
Gross Margin
73%
Country UK
Market Cap 163B GBP
Gross Margin
82%
Country CH
Market Cap 179.6B CHF
Gross Margin
75%
Country US
Market Cap 146B USD
Gross Margin
71%
No Stocks Found

BrightGene Bio-Medical Technology Co Ltd
Glance View

Market Cap
13.3B CNY
Industry
Pharmaceuticals

BrightGene Bio-Medical Technology Co., Ltd. engages in the research, development, and manufacturing of biopharmaceuticals, medicines as well as special generic active pharmaceutical ingredients and finished dosage forms. The company is headquartered in Suzhou, Jiangsu and currently employs 910 full-time employees. The company went IPO on 2019-11-08. The firm's main products include antifungal active pharmaceutical ingredients (APIs), antiviral APIs, immunosuppressive APIs, and other APIs and preparations. The firm's generic drugs mainly include entecavir, caspofungin, micafungin, posaconazole, everolimus and fondaparinux sodium. The firm mainly conducts its businesses in domestic and overseas markets.

Intrinsic Value
22.57 CNY
Overvaluation 28%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
55%
=
Gross Profit
682.4m
/
Revenue
1.2B
What is the Gross Margin of BrightGene Bio-Medical Technology Co Ltd?

Based on BrightGene Bio-Medical Technology Co Ltd's most recent financial statements, the company has Gross Margin of 55%.